<DOC>
	<DOC>NCT01067833</DOC>
	<brief_summary>To evaluate the safety, efficacy, and tolerability of 3 doses of K201 (oral) administered for up to 28 days in subjects with recent DC cardioversion to sinus rhythm from sustained symptomatic atrial fibrillation (AF duration &gt;3 days and &lt;6 months).</brief_summary>
	<brief_title>Phase 2 Study of Oral K201 for Prevention of AF Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Symptomatic AF (sustained &gt;3 days and &lt;6 months) and clinically indicated for cardioversion; Adequate anticoagulant therapy for cardioversion in accordance with standard practice as recommended by ACC/AHA/ESC guidelines or with local clinical practice; Hemodynamically stable (90 mmHg &lt; systolic blood pressure &lt; 190 mmHg)at screening and on Day 1; Known prolonged QT syndrome or QTc interval of &gt;0.500 sec at screening; familial long QT syndrome; previous Torsade de Pointes; ventricular fibrillation; or sustained ventricular tachycardia (VT); QRS &gt;0.130 sec; Previous episodes of second or thirddegree atrioventricular block; Unsuccessful DC cardioversion attempt within 3 months; prior ablation for AF; Persistent bradycardia with ventricular rate below 50 beats/min, sicksinus syndrome or pacemaker (including CRT, AICD); Myocardial infarction (MI), cardiac surgery, angioplasty, unstable angina or acute coronary syndrome within 30 days prior to entry into the study; NYHA Class III or Class IV heart failure (HF) at screening or admission, or hospitalized for HF in previous 6 months; Known concurrent temporary secondary causes of AF; Received a Class I or Class III antiarrhythmic agent (including sotalol) within 5 halflives of randomization or amiodarone or dronedarone within 4 weeks; Received treatment with other drugs known to prolong the QT interval within 5 halflives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>AF</keyword>
</DOC>